C-reactive protein in the Heart Protection Study - Authors' reply

The Lancet

Volumn 377, Issue 9781, 2011, Pages 1918-1919

  Emberson, Jonathan ^a   Bennett, Derrick ^a   Parish, Sarah ^a   Armitage, Jane ^a   Collins, Rory ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

DIABETES MELLITUS; HEART INFARCTION; HEART PROTECTION; LETTER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; STROKE;

EID: 79958173575     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60808-8     Document Type: Letter

References (5)

1. Heart Protection Study Collaborative Group C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Lancet 377 2011 469 476
2. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
3. Cholesterol Treatment Trialists Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
4. PM Ridker, E Danielson, FAH Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
5. PM Ridker, J MacFadyen, P Libby, RJ Glynn Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Am J Cardiol 106 2010 204 209